Canaccord analyst Richard Close raised the firm’s price target on LifeStance (LFST) to $9 from $8 and keeps a Buy rating on the shares. The firm updated its model to reflect opportunity amid an uncertain healthcare environment while the company could be insulated from much of the uncertainty in broader healthcare ecosystem, with payers continuing to be supportive of expanding in-network access to care.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFST: